Pleno Inc.
3 known investors
Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays. It targets clinical genomics applications such as oncology to support AI-driven precision medicine.
Investors · 3
Competitors · 3
by search overlapNeoGenomics7 shared keywordsNeoGenomics provides oncology diagnostics and laboratory testing, offering over 500 tests across modalities including molecular testing, IHC, flow cytometry, FISH, next-generation sequencing, and comprehensive genomic profiling for solid tumors and hematologic cancers. It serves oncologists, patients, and biopharma partners in the US, supporting clinical care as well as drug development and clinical trials.
ZAGENO5 shared keywords
Labcorp4 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.
Companies competing with Pleno Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Pleno Inc. do?
- Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays. It targets clinical genomics applications such as oncology to support AI-driven precision medicine.
- Who are Pleno Inc.'s investors?
- Pleno Inc.'s investors include Foresite Capital, Medical Excellence Capital, Deerfield Management Company.